

# Gregory S Day

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/63903/publications.pdf>

Version: 2024-02-01

103  
papers

3,496  
citations

257357

24  
h-index

155592

55  
g-index

109  
all docs

109  
docs citations

109  
times ranked

4743  
citing authors

#	ARTICLE	IF	CITATIONS
1	The temporal onset of the core features in dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2022, 18, 591-601.	0.4	19
2	LG11 antibody encephalitis: acute treatment comparisons and outcome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 309-315.	0.9	48
3	Deciphering the contributions of neuroinflammation to neurodegeneration: lessons from antibody-mediated encephalitis and coronavirus disease 2019. <i>Current Opinion in Neurology</i> , 2022, 35, 212-219.	1.8	8
4	Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus. <i>Neurology</i> , 2022, 98, 619-631.	1.5	24
5	Prevalence of Surgical Procedures at Symptomatic Onset of Prion Disease. <i>JAMA Network Open</i> , 2022, 5, e221556.	2.8	4
6	Clinicopathologic Factors Associated With Reversion to Normal Cognition in Patients With Mild Cognitive Impairment. <i>Neurology</i> , 2022, 98, .	1.5	7
7	Three cases of Creutzfeldt-Jakob disease presenting with a predominant dysexecutive syndrome. <i>Journal of Neurology</i> , 2022, 269, 4222-4228.	1.8	2
8	Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study. <i>Lancet Neurology</i> , The, 2022, 21, 329-341.	4.9	72
9	Autosomal dominant and sporadic late onset Alzheimer's disease share a common <i>in vivo</i> pathophysiology. <i>Brain</i> , 2022, 145, 3594-3607.	3.7	20
10	Life after autoantibody-mediated encephalitis: optimizing follow-up and management in recovering patients. <i>Current Opinion in Neurology</i> , 2022, 35, 415-422.	1.8	3
11	Alzheimer's disease cerebrospinal fluid biomarkers differentiate patients with Creutzfeldt-Jakob disease and autoimmune encephalitis. <i>European Journal of Neurology</i> , 2022, 29, 2905-2912.	1.7	4
12	Rapidly Progressive Dementia. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2022, 28, 901-936.	0.4	8
13	Flortaucipir (tau) PET in LG11 antibody encephalitis. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 491-497.	1.7	7
14	Clinical and Paraclinical Measures Associated with Outcome in Cerebral Amyloid Angiopathy with Related Inflammation. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 133-142.	1.2	12
15	Leveraging molecular biomarkers to make the common diagnosis in the uncommon patient. <i>Journal of Neuroimmunology</i> , 2021, 352, 577474.	1.1	2
16	Prospective Quantification of CSF Biomarkers in Antibody-Mediated Encephalitis. <i>Neurology</i> , 2021, 96, e2546-e2557.	1.5	38
17	Autoimmune Encephalitis in First Episode Psychoses. <i>Neurology</i> , 2021, 97, 16-17.	1.5	5
18	The Longitudinal Early-Onset Alzheimer's Disease Study (LEADS): Framework and methodology. <i>Alzheimer's and Dementia</i> , 2021, 17, 2043-2055.	0.4	34

#	ARTICLE	IF	CITATIONS
19	Autoimmune Neurology. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	9
20	<i>MAPT</i> R406W increases tau T217 phosphorylation in absence of amyloid pathology. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1817-1830.	1.7	11
21	Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study. <i>Lancet Neurology</i> , The, 2021, 20, 615-626.	4.9	26
22	Measuring the cognitive costs of the COVID-19 pandemic. <i>Molecular Neurodegeneration</i> , 2021, 16, 67.	4.4	1
23	Regional Age-Related Atrophy After Screening for Preclinical Alzheimer Disease. <i>Neurobiology of Aging</i> , 2021, 109, 43-51.	1.5	9
24	A Neurologist's Practical Approach to Cognitive Impairment. <i>Seminars in Neurology</i> , 2021, 41, 686-698.	0.5	0
25	Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary. <i>Neurology</i> , 2021, 97, 942-957.	1.5	58
26	An unexpected risk: Surgical procedures are common in patients with prion disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
27	Testing for <i>N</i> -methyl-D-aspartate Receptor Autoantibodies in Clinical Practice. <i>Canadian Journal of Neurological Sciences</i> , 2020, 47, 69-76.	0.3	6
28	Overcoming Neurophobia With the Help of Peruvian Talking Bears. <i>JAMA Neurology</i> , 2020, 77, 291.	4.5	0
29	Serum neurofilament light chain uncovers neurodegeneration early in the course of Alzheimer's disease. <i>Brain</i> , 2020, 143, 3521-3522.	3.7	1
30	The Road to Recovery: A Pilot Study of Driving Behaviors Following Antibody-Mediated Encephalitis. <i>Frontiers in Neurology</i> , 2020, 11, 678.	1.1	5
31	Tau kinetics in Alzheimer disease and primary tauopathies. <i>Alzheimer's and Dementia</i> , 2020, 16, e039109.	0.4	0
32	Amyloid and tau PET in sporadic early-onset Alzheimer's disease: Preliminary results from LEADS. <i>Alzheimer's and Dementia</i> , 2020, 16, e041613.	0.4	2
33	Increased white matter MRI T1 hypointensity volume in young-onset Alzheimer's disease patients is not accounted for by age or cardiovascular risk factors. <i>Alzheimer's and Dementia</i> , 2020, 16, e045577.	0.4	0
34	Neurodegeneration in the Longitudinal Evaluation of Early Onset Alzheimer's Disease Study (LEADS) sample: Results from the MRI core. <i>Alzheimer's and Dementia</i> , 2020, 16, e046338.	0.4	0
35	Sex-associated differences in pathology burden in early-onset Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e046532.	0.4	2
36	Assessing the Reliability of Reported Medical History in Older Adults. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 643-652.	1.2	3

#	ARTICLE	IF	CITATIONS
37	Improving thiamine prescribing at an academic hospital network using the computerized provider order entry system: a cohort study. <i>CMAJ Open</i> , 2020, 8, E383-E390.	1.1	3
38	Sleep Disturbances in Patients with Autoimmune Encephalitis. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 28.	2.0	18
39	Searching for autoimmune encephalitis: Beware of normal CSF. <i>Journal of Neuroimmunology</i> , 2020, 345, 577285.	1.1	30
40	Select Atrophied Regions in Alzheimer disease (SARA): An improved volumetric model for identifying Alzheimer disease dementia. <i>NeuroImage: Clinical</i> , 2020, 26, 102248.	1.4	24
41	Deciphering the factors that influence participation in studies requiring serial lumbar punctures. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12003.	1.2	9
42	An Elderly Man with Dementia. <i>Clinical Chemistry</i> , 2020, 66, 415-420.	1.5	3
43	Assessing the reliability of reported medical history in older adults. <i>Alzheimer's and Dementia</i> , 2020, 16, e042984.	0.4	0
44	Association of Acquired and Heritable Factors With Intergenerational Differences in Age at Symptomatic Onset of Alzheimer Disease Between Offspring and Parents With Dementia. <i>JAMA Network Open</i> , 2019, 2, e1913491.	2.8	11
45	Oculopalatal Tremor Following Pontine Hemorrhage. <i>Neurohospitalist, The</i> , 2019, 9, 241-242.	0.3	1
46	ICâ€Pâ€166: TAU PET IMAGING IN LGI1 ENCEPHALITIS: DECIPHERING THE CONTRIBUTORS TO COGNITIVE IMPAIRMENT IN AUTOIMMUNE ENCEPHALITIS. <i>Alzheimer's and Dementia</i> , 2019, 15, P131.	0.4	0
47	Author response: In vivo [ <sup>18</sup> F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. <i>Neurology</i> , 2019, 92, 150-150.	1.5	2
48	Structural signature of sporadic Creutzfeldtâ€ Jakob disease. <i>European Journal of Neurology</i> , 2019, 26, 1037-1043.	1.7	1
49	Sleep disturbances are common in patients with autoimmune encephalitis. <i>Journal of Neurology</i> , 2019, 266, 1007-1015.	1.8	52
50	Patient Stakeholder Versus Physician Preferences Regarding Amyloid PET Testing. <i>Alzheimer Disease and Associated Disorders</i> , 2019, 33, 246-253.	0.6	9
51	Patient characteristics and outcome associations in AMPA receptor encephalitis. <i>Journal of Neurology</i> , 2019, 266, 450-460.	1.8	60
52	Reversible Dementias. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2019, 25, 234-253.	0.4	5
53	Reader response: Unintended consequences of Mayo paraneoplastic evaluations. <i>Neurology</i> , 2019, 93, 603-603.	1.5	10
54	Positive Allosteric Modulation as a Potential Therapeutic Strategy in Anti-NMDA Receptor Encephalitis. <i>Journal of Neuroscience</i> , 2018, 38, 3218-3229.	1.7	39

#	ARTICLE	IF	CITATIONS
55	Autoimmune Encephalitis With Multiple Autoantibodies. <i>Neurologist</i> , 2018, 23, 55-59.	0.4	14
56	Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis. <i>Neurology</i> , 2018, 90, 789-800.	1.5	107
57	Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. <i>Neurology</i> , 2018, 90, 777-788.	1.5	406
58	In vivo [ <sup>18</sup> F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. <i>Neurology</i> , 2018, 90, e896-e906.	1.5	27
59	Practice guideline update summary: Mild cognitive impairment. <i>Neurology</i> , 2018, 90, 126-135.	1.5	1,263
60	Rapidly Progressive Dementia in the Outpatient Clinic: More Than Prions. <i>Alzheimer Disease and Associated Disorders</i> , 2018, 32, 291-297.	0.6	12
61	Long-Term Cognitive Outcomes in Patients with Autoimmune Encephalitis. <i>Canadian Journal of Neurological Sciences</i> , 2018, 45, 540-544.	0.3	44
62	Autoimmune Dementia. <i>Seminars in Neurology</i> , 2018, 38, 303-315.	0.5	19
63	Discovery and validation of autosomal dominant Alzheimer's disease mutations. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 67.	3.0	29
64	Identifying priority outcomes that influence selection of disease-modifying therapies in MS. <i>Neurology: Clinical Practice</i> , 2018, 8, 179-185.	0.8	23
65	Author response: Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. <i>Neurology</i> , 2018, 91, 373-374.	1.5	25
66	Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease. <i>Neurology</i> , 2017, 88, 1273-1281.	1.5	34
67	Tau-PET Binding Distinguishes Patients With Early-stage Posterior Cortical Atrophy From Amnesic Alzheimer Disease Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2017, 31, 87-93.	0.6	52
68	Rethinking Outcomes in Leucine-Rich, Glioma-Inactivated 1 Protein Encephalitis. <i>JAMA Neurology</i> , 2017, 74, 19.	4.5	10
69	Teaching Neuro Images: Cerebral amyloid angiopathy-related inflammation presenting with isolated leptomeningitis. <i>Neurology</i> , 2017, 89, e66-e67.	1.5	7
70	[P301]: FLORTAUCIPIR TAU-PET SPECIFICITY IS MAINTAINED IN PATIENTS WITH PATHOLOGICALLY CONFIRMED CREUTZFELDT-JAKOB DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P900.	0.4	0
71	[P257]: DECODING VARIABILITY IN AGE-AT-SYMPTOMATIC-ONSET BETWEEN PARENTS AND CHILDREN WITH SPORADIC ALZHEIMER DISEASE DEMENTIA. <i>Alzheimer's and Dementia</i> , 2017, 13, P1041.	0.4	0
72	[P180]: FLORTAUCIPIR TAU-PET SPECIFICITY IS MAINTAINED IN PATIENTS WITH PATHOLOGICALLY CONFIRMED CREUTZFELDT-JAKOB DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P134.	0.4	0

#	ARTICLE	IF	CITATIONS
73	P2-203: Phenotypic Similarities between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease: A Single-Family Case-Control Study. <i>Alzheimer's and Dementia</i> , 2016, 12, P698.	0.4	0
74	P4-131: Evaluating the Contributions of Common Neurodegenerative Dementing Illnesses to Rapidly Progressive Dementia in the Outpatient Clinic. <i>Alzheimer's and Dementia</i> , 2016, 12, P1063.	0.4	0
75	P4-337: IN VIVO Quantification of Regional TAU Deposition in Patients with Progressive Posterior Cortical Dysfunction. , 2016, 12, P1163-P1164.		0
76	N-methyl-D-aspartate receptor encephalitis mediates loss of intrinsic activity measured by functional MRI. <i>Journal of Neurology</i> , 2016, 263, 1083-1091.	1.8	21
77	Anti N-methyl-D-aspartate receptor encephalitis: a game-changer?. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 849-859.	1.4	5
78	Phenotypic Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease. <i>JAMA Neurology</i> , 2016, 73, 1125.	4.5	17
79	A Case Study in the History of Neurology. <i>Neurohospitalist, The</i> , 2016, 6, 181-184.	0.3	3
80	Over-Prescribed Medications, Under-Appreciated Risks: A Review of the Cognitive Effects of Anticholinergic Medications in Older Adults. <i>Missouri Medicine</i> , 2016, 113, 207-14.	0.3	15
81	<i>GRIN1</i> polymorphisms do not affect susceptibility or phenotype in NMDA receptor encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e153.	3.1	5
82	P2-108: Differentiating corticobasal degeneration and Alzheimer disease by longitudinal clinical and cognitive features. , 2015, 11, P525-P525.		0
83	Thiamine prescribing practices within university-affiliated hospitals: A multicenter retrospective review. <i>Journal of Hospital Medicine</i> , 2015, 10, 246-253.	0.7	17
84	Fanning the Flames in Anti-N-methyl-D-aspartate Receptor Encephalitis. <i>International Journal of Gynecological Pathology</i> , 2015, 34, 401-402.	0.9	0
85	Cognitive decline in an older physician. <i>Cmaj</i> , 2015, 187, 750-754.	0.9	1
86	Teaching Neuro Images : Recurrent SSPE presenting as Anton syndrome with cortical ribboning. <i>Neurology</i> , 2015, 85, e141-2.	1.5	4
87	When dementia progresses quickly: a practical approach to the diagnosis and management of rapidly progressive dementia. <i>Neurodegenerative Disease Management</i> , 2014, 4, 41-56.	1.2	92
88	Lateral medullary syndrome: a diagnostic approach illustrated through case presentation and literature review. <i>Canadian Journal of Emergency Medicine</i> , 2014, 16, 164-170.	0.5	29
89	Abnormal Neurons in Teratomas in NMDAR Encephalitis. <i>JAMA Neurology</i> , 2014, 71, 717.	4.5	78
90	The rapidly expanding world of rapidly progressive encephalopathy. <i>Annals of Neurology</i> , 2014, 75, 334-336.	2.8	2

#	ARTICLE	IF	CITATIONS
91	<scp>LGI</scp>1 autoantibodies associated with cerebellar degeneration. <i>Neuropathology and Applied Neurobiology</i> , 2014, 40, 645-649.	1.8	9
92	How noise correlations impact the amount of information in superior colliculus: the analysis of a population with shared receptive fields. <i>BMC Neuroscience</i> , 2014, 15, .	0.8	0
93	Wernicke encephalopathy: a medical emergency. <i>Cmaj</i> , 2014, 186, E295-E295.	0.9	31
94	Anti-NMDA receptor encephalitis in children. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2013, 112, 1229-1233.	1.0	18
95	Saliency Network Resting-State Activity. <i>JAMA Neurology</i> , 2013, 70, 1249-53.	4.5	70
96	Autoimmune synaptic protein encephalopathy syndromes and the interplay between mental health, neurology and immunology. <i>Health Science Inquiry</i> , 2013, 4, .	0.1	0
97	Anti-NMDA receptor encephalitis. The disorder, the diagnosis and the immunobiology. <i>Autoimmunity Reviews</i> , 2012, 11, 863-872.	2.5	155
98	Investigating the role of the superior colliculus in active vision with the visual search paradigm. <i>European Journal of Neuroscience</i> , 2011, 33, 2003-2016.	1.2	44
99	Anti-NMDA-Receptor Encephalitis: Case Report and Literature Review of an Under-Recognized Condition. <i>Journal of General Internal Medicine</i> , 2011, 26, 811-816.	1.3	77
100	Rosary-Like Pattern Calcified Lesions: An Unusual Manifestation of Ipsilateral Carotid Artery Stenosis. <i>Cerebrovascular Diseases</i> , 2009, 28, 536-536.	0.8	0
101	Statistical estimation and comparison of group-specific bivariate correlation coefficients in family-type clustered studies. <i>Journal of Applied Statistics</i> , 0, , 1-25.	0.6	2
102	Cross-Sectional and Longitudinal Comparisons of Biomarkers and Cognition Among Asymptomatic Middle-Aged Individuals with a Parental History of Either Autosomal Dominant or Late Onset Alzheimer Disease. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
103	Patterns and implications of neurological examination findings in autosomal dominant Alzheimer disease. <i>Alzheimer's and Dementia</i> , 0, , .	0.4	2